Corcept Therapeutics CORT Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Regeneron PharmaceuticalsREGN

$198.6M+10.6%

ExelixisEXEL

——

CytokineticsCYTK

——

Praxis Precision Medicines, Inc.PRAX

——

IncyteINCY

——

Summit TherapeuticsSMMT

——

Other financials

Income statement

See full

Revenue$164.9M+4.9%

Gross profit$162.0M+4.7%

Operating income-$49.6M-1,552%

Net income-$31.8M-255%

EPS (diluted)-$0.30-276%

Balance sheet

See full

Cash & equivalents$110.0M+21.1%

Total debt$9.6M+41.0%

Total equity$638.0M-6.6%

Total assets$814.9M-3.7%

Cash flow

See full

Operating cash flow-$16.8M-452%

CapEx$201.0K+93.3%

Free cash flow-$17.0M-464%

Valuation

See full

Market cap$8.58B-64.4%

Enterprise value$8.48B-65.0%

P/E181.2×+1.3×

P/S11.2×-24.0×

Profitability

See full

Gross margin98.3%-0.2pp

Operating margin-1.1%-17.2pp

Net margin6.2%-13.4pp

FCF margin15.6%-10.2pp

Returns & leverage

See full

Return on equity7.2%-14.6pp

Debt / equity0×0.0×

Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Corcept Therapeutics's increase (decrease) in prepaid expense and other assets?: Corcept Therapeutics (CORT) reported increase (decrease) in prepaid expense and other assets of -$4.74M in Q1 2026.
How has Corcept Therapeutics's increase (decrease) in prepaid expense and other assets changed year-over-year?: Corcept Therapeutics's increase (decrease) in prepaid expense and other assets decreased by 135.0% year-over-year, from $13.53M to -$4.74M.